HomeLBank Stocks
Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc (INO)

24HHigh$1.6424HLow$1.37
$1.64
+0.18%

Last updated: 2026-11-18 11:01:03

K-Line Chart, actual market data is subject to the trading page.

Key Data

Prev. Open
$1.38
Prev. Close
$1.64
Prev. Day's Range
$1.37 - $1.64
52W Range
$0.56 - $2.72
Trading Volume
15.085M
MC
$262.23M
P/E Ratio
--
EPS
$-0.58

Company Overview

NASDAQ

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA drugs to treat and protect people from diseases associated with the human papillomavirus (HPV), cancer, and infectious diseases.

SectorHEALTHCARE
IndustryBIOTECHNOLOGY
Headquarters660 WEST GERMANTOWN PIKE, PLYMOUTH MEETING, PA, UNITED STATES, 19462
CountryUSA
Listing Date1998-12-08
Fiscal Year Ended2026-09-30
Shares Outstanding187.307M
CIK Code1055726

Financial Metrics

Indicator2026-06-302026-03-312025-12-312025-09-30
Income$0$0-$65.343K$0
Operating Expenses--$745.464K$754.054K$749.656K
Net Income-$6.012M-$19.683M$3.765M-$45.497M
Net Profit Margin-----5761.7%--
Earnings Per Share--$-0.03$0.01$-0.87
EBITDA-$5.69M-$18.937M$4.519M-$44.747M
Effective Tax Rate--------

FAQ

Inovio Pharmaceuticals, Inc. (INO) is a biotechnology company focused on developing DNA-based immunotherapies and vaccines to treat and prevent infectious diseases, cancer, and other conditions. The company utilizes its proprietary DNA medicines platform to create treatments designed to activate the immune system.
Inovio Pharmaceuticals, Inc. operates in the Healthcare sector and is categorized within the Biotechnology industry. It specializes in the development of advanced immunotherapies and DNA-based solutions targeting unmet medical needs.
As a biotechnology company, Inovio Pharmaceuticals' revenue is primarily driven by collaboration agreements, research grants, and potential licensing of its DNA-based technology. Additionally, future revenue may hinge on the successful commercialization of its therapies and vaccines currently in development.
Investing in Inovio Pharmaceuticals carries risks typical of biotech companies, including dependency on clinical trial success, regulatory approvals, and funding for research and development. Additionally, competition from other biotech firms and market volatility in the healthcare sector may pose challenges.
Inovio differentiates itself with its proprietary DNA medicines platform, which focuses on developing therapies designed to trigger targeted immune responses. This innovative technology distinguishes it from competitors utilizing more traditional biopharmaceutical approaches.
No, Inovio Pharmaceuticals does not currently pay a dividend to shareholders. As a biotechnology company focused on research and development, it typically reinvests its resources into advancing its pipeline of therapeutics and vaccines.
Key opportunities for Inovio Pharmaceuticals include its potential to address unmet medical needs with its DNA-based therapies, the ability to secure strategic partnerships, and the advancement of its pipeline into later-stage clinical trials, which could lead to regulatory approvals and commercialization.
Inovio Pharmaceuticals faces competition from other biotechnology companies developing immunotherapies and treatments, such as Moderna, BioNTech, and Novavax. These firms also focus on vaccines and therapies for infectious diseases and cancers, presenting competition in both innovation and market share.
Risk Warning
  1. 1.Stock prices may fluctuate significantly; invest with caution. Past performance is not indicative of future results.
  2. 2.Digital asset trading involves multiple risks, including market and technical risks. Please make rational decisions and allocate assets wisely.
  3. 3.The information contained on this page is for reference only and does not constitute any investment advice.